Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.375
Bid: 4.25
Ask: 4.50
Change: -0.025 (-0.57%)
Spread: 0.25 (5.882%)
Open: 4.625
High: 4.625
Low: 4.25
Prev. Close: 4.40
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement for AIHL test

24 Apr 2020 07:00

RNS Number : 7231K
Genedrive PLC
24 April 2020
 

genedrive plc

("genedrive" or the "Company")

 

Distribution agreement for AIHL test

 

 Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland

Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a contract for the distribution of the Company's Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland with Inspiration Healthcare Group plc (AIM: IHC) ("Inspiration Healthcare"). The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

 

David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."

 

The Genedrive® MT-RNR1 test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE).

 

Neil Campbell, Chief Executive Officer of Inspiration Healthcare, commented: "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to antibiotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

 

genedrive plc

 

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, Antibiotic Induced Hearing Loss, and has tests in development for tuberculosis (mTB) and SARS-CoV-2.

 

About Inspiration Healthcare (http://www.inspiration-healthcare.com)

 

Inspiration Healthcare is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

 

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe. In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGREAELDAASEEAA
Date   Source Headline
24th Apr 20243:36 pmRNSClinical Trial Agreement
3rd Apr 20245:00 pmRNSApplication for Listing & Total Voting Rights
3rd Apr 20247:00 amRNSNICE recommends the Genedrive CYP2C19-ID Kit
28th Mar 20247:00 amRNSHalf-year Report
26th Mar 20247:00 amRNSInvestor presentation
19th Mar 20243:53 pmRNSApplication for Listing & Total Voting Rights
15th Mar 202412:30 pmRNSReceipt of R&D tax credit
19th Feb 20247:00 amRNSNICE Early Value Assessment update
6th Feb 20242:03 pmRNSDirector/PDMR Shareholding
2nd Feb 20243:35 pmRNSTotal Voting Rights
19th Jan 20244:14 pmRNSTotal Voting Rights
15th Jan 20243:21 pmRNSTotal Voting Rights
10th Jan 20247:00 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSEquity Prepayment Facility drawdown
29th Dec 202311:44 amRNSResult of AGM
20th Dec 20234:57 pmRNSTotal Voting Rights
20th Dec 20237:00 amRNSInitial overseas orders of MT-RNR1 ID kit
7th Dec 20237:00 amRNSTotal Voting Rights
6th Dec 20237:00 amRNSPosting of annual report and notice of AGM
6th Dec 20237:00 amRNSTotal Voting Rights
4th Dec 20231:13 pmRNSMT-RNR1 ID kit adopted for routine use in Brighton
30th Nov 20235:29 pmRNSBlock listing Interim Review
30th Nov 20237:00 amRNSFinal Results
29th Nov 20235:25 pmRNSEquity Prepayment Facility drawdown
16th Nov 20237:00 amRNSNotice of Results
20th Oct 202310:52 amRNSTotal Voting Rights
28th Sep 202312:35 pmRNSc£1.2m grant awarded
21st Sep 20232:39 pmRNSApplication for listing & total voting rights
11th Sep 20232:17 pmRNSBoard changes
6th Sep 20237:00 amRNSUKCA marking achieved for new CYP2C19 test
4th Aug 20234:00 pmRNSTotal Voting Rights
5th Jul 20239:11 amRNSEquity Prepayment Facility drawdown
16th Jun 20232:28 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSMulti-partner grant awarded
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.